Cargando…

Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement

The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), i...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Ryan, Stehli, Annamarie, Nguyen, Hiep, Leu, Szu-Yun, Nguyen, Danh V, Schwarzkopf, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483539/
https://www.ncbi.nlm.nih.gov/pubmed/26157529
http://dx.doi.org/10.2174/1874325001509010129
Descripción
Sumario:The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), including increased body weight, age, gender, end stage renal disease (ESRD), smoking, and peri-operative transfusion. Chart review identified 249 patients for study inclusion. Logistic regression (LR) was used to identify associated risk factors for a subtherapeutic INR (<1.8) on day of discharge. The majority of patients (58.6%, 146 of 249) following TJA surgery were found to have a subtherapeutic INR level (INR<1.8) at discharge (mean length of stay 2.6 days). Multivariate LR analysis found that weight greater than 180 lbs. (OR 2.08, CI 1.09, 3.98, P=0.027) was found to increase the odds of a subtherapeutic INR on day of discharge. Our results were not significant for weight 20% beyond ideal body weight, age (>65y), gender, peri-operative transfusion, smoking, ESRD or autoimmune disease. A patient’s body weight influences response to warfarin following TJA. An inpatient warfarin dosing nomogram that takes into account a patient’s weight should be used to reduce the risk of subtherapeutic INR levels in obese TJA patients.